The Standing National Committee on Medicines (SNCM), in its recommendation, included coronary stents in the NLEM, 2022 in two categories --...

This means that the firm has provided adequate justification to the government for launching its product at “any price" it wants. Meril Lif...

The development follows a price revision as per annual Wholesale Price Index (WPI) at the rate of 3.44 percent increase, the National Pharm...

The company asserted that its decision to withdraw Abbott was based on “low commercial uptake” and this was reflected in the sales figures ...

The government is expected to hold discussions to decide on these requests only in February, a year after it first capped prices of these l...

Abbott publicly announced intentions to stop global sales of dissolvable scaffold ‘Absorb’, which has been mired in controversy for risks r...

Abbott’s move also comes while several regulators in different countries have scrutinised this scaffold, used in life saving procedures, ov...

The development comes in the wake of several studies showing that bioresorbable cardiac stents are not only not superior to existing DES, b...

As per the government, the NPPA was closely monitoring the situation and has alerted the state governments and state drugs controllers to m...

Unlike drug-eluting stents that are made of metal and stay in the arteries forever, Meril’s 100 micron-thick BVS ‘MeRes100’ is made of mate...

Now, patients purchasing stents at their maximum price won’t pay hospitals margins of more than Rs 2,400 on DES and BVS and about Rs 581 on...

According to data from the drug pricing regulator, hospitals were found earning exorbitant margins on stents—over 650% in some cases.

"Price capping will make stents more affordable and accessible to patients and new prices leave enough margins to the industry to grow," he...

Cardiologists told TOI on Thursday the bioresorbable vascular scaffold (BVS)— the fourth generation and most recent one that dissolves into...

In a notification, the drug regulator has capped the ceiling prices of stentsat Rs 29,600, which currently costs between Rs 40,000 to Rs 1....

The National Pharmaceutical Pricing Authority (NPPA) has also called for a meeting with the stakeholders to discuss the issue on January 24.

The decision of the Department of Pharmaceuticals comes months after the Ministry of Health in July included stents in the National List of...